CARB-X is funding French biotech Mutabilis to develop a new class of antibacterials to treat infections caused by carbapenem-resistant Enterobacterales
CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.